Ledger.Open graph →
SEC Form D · Amendment · filed August 14, 2024

Odyssey Therapeutics, Inc

Offering
$121.1M
Sold
$117.2M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Boston, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (25)

Jill D. Carroll · Boston, MADirectorJeffrey D. Leiden · Boston, MADirectorLorence M. Kim · Boston, MADirectorTimothy D. Walbert · Boston, MADirectorValerie D. Odegard · Boston, MADirectorGary D. Glick · Boston, MAExec · DirectorCarl D. Gordon · Boston, MADirectorLorence M. Kim · Boston, MADirectorJeffrey D. Leiden · Boston, MADirectorValerie D. Odegard · Boston, MADirectorJill D. Carroll · Boston, MADirectorGary D. Glick · Boston, MAExec · DirectorCarl D. Gordon · Boston, MADirectorTimothy D. Walbert · Boston, MADirectorCharles M. Baum · San Diego, CADirectorIan M. Smith · Boston, MADirectorTravis C. Miller · Wilmington, DEDirectorJohn C. Gillam · Wilmington, DEExec · DirectorRoger K. Coit · Walnut Creek, CADirectorPatrick L. Reilly · WALNUT CREEK, CADirectorChristopher Mayer · Mt Airy, MDDirectorAdam Lilling · Venice, CADirectorDavid Grant · Plano, TXDirectorCharles M. Baum · San Diego, CADirectorIan M. Smith · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗